Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05657834 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects
A Phase 1 study, sponsored by Sagimet Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT05657834 is a Phase 1 study that has completed, run by Sagimet Biosciences. The registered enrollment target is 8 participants.
The verdict
NCT05657834, a Phase 1 study, has completed, sponsored by Sagimet Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]TVB-2640 healthy male subjects.
Interventions
- DRUG [14C]-TVB-2640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-11-21 |
| Est. Completion | 2022-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05657834
The ClinicalTrials.gov registry entry for NCT05657834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sagimet Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-TVB-2640 is the first listed.
NCT05657834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05657834 about?
NCT05657834 is a clinical study titled "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects". A Phase 1, Open-label Study of the absorption, metabolism, and excretion of a single oral dose of \[14C\]TVB-2640 healthy male subjects.
What is the current status of trial NCT05657834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2022-11-21. Estimated completion is 2022-12-21.
What interventions are being tested in trial NCT05657834?
The interventions under investigation include: [14C]-TVB-2640 (DRUG).
Who is sponsoring clinical trial NCT05657834?
This trial is sponsored by Sagimet Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.